News Update

India trying for UNSC permanent membership through G-4 and L-69 countries groupingsNo proposal to set up Integrated Check Post at Shikarpur in Nadia district in WB: MoSPHD favours early rejig of GST tax rates structureGulf countries in consultation with Indian embassies restore pre-COVID minimum referral wagesIndia repatriated 60 lakh people under Vande Bharat Mission till April 30, 2021: MEABoxer Lovlina ends up bagging Bronze Medal at OlympicsCOVID-19 - China reports 71 cases - highest since January!Etched in stone - Oldest record of revenue evasionOf Sense & ServersTo frame assessment on best judgment basis, assessee's history is only relevant when conditions in which business activity is being conducted are similar to those of earlier period: ITATCBDT notifies Ontario Inc u/s 10(23FE) for eligible investment in IndiaSteel silos on PPP mode built at 7 locations: GovtDGTR terminates anti-dumping investigation against Self-adhesive Polyvinyl Chloride Film from China but recommends existing anti-dumping duty on Ceramic Tableware & Kitchenware from China and MalaysiaFor allowing of interest on borrowed funds u/s 36(1)(iii) of the Act, what is required is only whether borrowed funds were used by assessee for purpose of business : ITATCOVID-19 global death toll - Close to 10000 in last 24 hours - 1238 in Brazil & 1598 in IndonesiaMany steps taken to ensure smooth supply of Essential Drugs: GovtSC rules Ayurvedic Doctors to retire at 65 like AllopathicOrder passed u/s 201(1) is not sustainable where passed beyond period of 2 years end of FY in which last TDS statement is filed : ITATGovt notifies Delhi CBI Court for dealing with PMLA cases relating to 2G Spectrum ScamExport of Drug Formulations and Biologics registers continuous growthCOVID-19: Global tally of cases goes beyond 20 Crore + US reports 1.5 lakh new cases with over 500 deaths + 43K cases in India with 560 deaths + 22K cases in UK with 138 deathsDeduction u/s 37(1) cannot be allowed in respect of those expenses which are not proven to have been incurred wholly & exclusively for business purposes : ITATGovt not to charge fee on renewal of registration of electric vehiclesCBDT further stretches timelines for e-filing of various Forms including equalisation levy
 
CSIR-Laxai get DCGI nod to begin Colchicine trials on Covid patients

By TIOL News Service

NEW DELHI, JUN 12, 2021: THE Council of Scientific and Industrial Research (CSIR) and Laxai Life Sciences have received approval from the Drug Controller General of India (DCGI) to undertake a two-arm phase-2 clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients.

Colchicine is a drug used for treating gout and related inflammatory conditions. In combination with standard care, it will be an important therapeutic intervention for Covid patients with cardiac comorbidities and also for reducing pro-inflammatory cytokines, leading to faster recovery.

A number of global studies have confirmed that cardiac complications during the course of COVID-19 infection and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs.

The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT) in Hyderabad and the CSIR-Indian Institute of Integrative Medicine (IIIM) in Jammu.

The enrolment of patients has already begun at multiple sites across the country and the trial is likely to be completed in the next 8-10 weeks.

The phase-2 clinical efficacy trial of Colchicine may lead to life-saving interventions in the management of hospitalised patients. The drug can be made available to large population based on the results of the trial and regulatory approval.

"India is one of the largest producers of this key drug and if successful, it will be made available to the patients at an affordable cost," said a statement from the Ministry of Science and Technology.

Recent clinical studies in leading medical journals have found colchicine being associated with a significant reduction in the rates of recurrent pericarditis, post-pericardiotomy syndrome, and peri-procedural atrial fibrillation following cardiac surgery and atrial fibrillation ablation.


POST YOUR COMMENTS